Increased levels of SMAD7 were observed in approximately 50% of pancreatic cancer cases, with increased SMAD7 and YAP1 mRNA expression found to contribute to resistance against TGF-β signaling in this condition (38). This evidence concerns the gene SMAD7 and pancreatic neoplasm.